PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease Reportscolorectal neoplasms
MeSH D015179 - colorectal neoplasms
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D012002:Rectal diseases
0 Companies
0 Drugs
Success rate
D003108:Colonic diseases
5 Companies
1 Drug
$
Success rate
D007414:Intestinal neoplasms
0 Companies
0 Drugs
Success rate
D015179: 
Colorectal neoplasms
56 Companies
26 Drugs
$
Success rate
D012004:Rectal neoplasms
35 Companies
2 Drugs
$
Success rate
D003110:Colonic neoplasms
47 Companies
6 Drugs
$
Success rate
D003123:Hereditary nonpolyposis colorectal neoplasms
0 Companies
0 Drugs
Success rate
D011125:Adenomatous polyposis coli
28 Companies
3 Drugs
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaCapecitabine Capecitabine  2013-09-16   
Capecitabine Capecitabine Teva  2012-04-20   
Oxaliplatin Oxaliplatin  2009-08-07   
Streptozocin Zanosar  1982-05-07   
Novast LaboratoriesOxaliplatin Oxaliplatin  2018-10-16   
MylanBevacizumab Abevmy  2021-04-21   
Bevacizumab Lextemy     
Oxaliplatin Oxaliplatin  2012-08-07   
RocheBevacizumab Avastin  2005-01-12 $1,987.484 M Q4/22-Q3/23 
Ribavirin, Peginterferon alfa-2a Pegasys Copegus  2004-06-04   
Interferon alfa-2a Roferon-A  1986-06-04   
SandozOxaliplatin Oxaliplatin  2009-08-07   
SanofiOxaliplatin Eloxatin  2002-08-09   
Aflibercept Zaltrap  2013-02-01   
Merck Sharp & DohmeCetuximab Erbitux  2004-06-29   
Interferon alfa-2b Intron A  1986-06-04   
Interferon alfa-2b IntronA  2000-03-09   
Interferon alfa-2b Viraferon  2000-03-09   
BayerRegorafenib Stivarga 2022-06-28 2012-09-27   
PfizerBevacizumab Zirabev  2019-06-27 $424 M Y2023 
Eli LillyRamucirumab Cyramza  2014-04-21 $967.8 M Q2/23-Q1/24 
1
2
3
4
5
6
>
Clinical Trials
Historical Success Rate
Phase 1
79%
215/272
Phase 2
32%
105/331
Phase 3
38%
58/153
Approved: 27Overall Success rate: 10%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Teva
Capecitabine
Mylan
Bevacizumab
Roche
Bevacizumab,
Ribavirin,
Peginterferon alfa-2a,
Interferon alfa-2a,
Antithrombin iii,
Tiragolumab,
Inavolisib,
Idasanutlin,
Enzastaurin,
ETRUMADENANT,
Imgatuzumab,
Sodium chloride,
CIBISATAMAB,
SELICRELUMAB,
VANUCIZUMAB,
Retinol,
Ro7122290,
Polypepi1018,
Diprosone
Sanofi
Aflibercept,
Oxaliplatin,
Antithrombin iii,
Vitamin e,
Ziv-aflibercept,
Xaliproden,
PIMASERTIB,
SERIBANTUMAB,
VOXTALISIB,
Retinol,
Sr57746a,
Fluoropyrimidine,
Kd018
Merck Sharp & Dohme
Ribavirin,
Interferon alfa-2b,
Cetuximab,
Peginterferon alfa-2b,
E-7386,
Rintatolimod,
Transplatin,
Antithrombin iii,
Vitamin e,
Epacadostat,
Aglatimagene besadenovec,
Vicriviroc,
Tirapazamine,
Calcium dobesilate,
Regramostim,
Terfenadine,
GRAPIPRANT,
EFINEPTAKIN ALFA,
OLAPTESED PEGOL,
Methylcobalamin,
Sodium chloride,
DALOTUZUMAB,
Quavonlimab,
ROBATUMUMAB,
TEMUTERKIB,
TOZASERTIB,
VACTOSERTIB,
Vibostolimab,
Retinol,
Mk-4280,
Ngm707,
Capeox,
Ngm438,
Nc410,
Bca101,
Gb1275
Bayer
Regorafenib,
Angiotensin ii,
Vitamin k,
Ziv-aflibercept,
Vatalanib,
Perindopril,
Gadoxetic acid,
Retinol
Pfizer
Bevacizumab,
TOMIVOSERTIB,
Transplatin,
Antithrombin iii,
Vitamin e,
Sasanlimab,
Aglatimagene besadenovec,
Buparlisib,
Figitumumab,
Semaxanib,
MIRDAMETINIB,
ASCRINVACUMAB,
Gedatolisib,
PELITREXOL,
PONSEGROMAB,
Retinol
Eli Lilly
Ramucirumab,
Transplatin,
Albumin,
Vitamin e,
Aglatimagene besadenovec,
Pegilodecakin,
Galunisertib,
Enzastaurin,
Calcium dobesilate,
Pegargiminase,
Methylcobalamin,
CIXUTUMUMAB,
LITRONESIB,
MERESTINIB,
PREXASERTIB,
RALIMETINIB,
SAMOTOLISIB,
TEMUTERKIB,
Retinol,
Ly3499446
1
2
3
4
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use